Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2002
10/31/2002CA2443600A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002CA2443587A1 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/31/2002CA2443373A1 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002CA2442994A1 Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
10/31/2002CA2442591A1 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
10/31/2002CA2442112A1 Use of creatine for the amelioration of oxidative stress
10/30/2002EP1253201A2 Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor
10/30/2002EP1253141A1 Substituted carbazoles as tubulin polymerization inhibitors and their use for the treatment of cancer
10/30/2002EP1253139A2 Multioligoanilinated fullerenes
10/30/2002EP1252894A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions
10/30/2002EP1252519A2 Methods for detecting cancer of the central nervous system
10/30/2002EP1252333A2 Methods and materials relating to cd84-like polypeptides and polynucleotides
10/30/2002EP1252323A2 Virus strains for the oncolytic treatment of cancer
10/30/2002EP1252322A2 Herpes virus strains for gene therapy
10/30/2002EP1252309A2 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
10/30/2002EP1252308A2 Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides
10/30/2002EP1252306A1 Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr
10/30/2002EP1252300A2 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
10/30/2002EP1252298A2 Phosphodiesterases
10/30/2002EP1252188A2 G-protein coupled receptors
10/30/2002EP1252177A1 Ligand for vascular endothelial growth factor receptor
10/30/2002EP1252175A1 Antisense modulation of survivin expression
10/30/2002EP1252164A1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid
10/30/2002EP1252163A2 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
10/30/2002EP1252162A1 Alpha v integrin receptor antagonists
10/30/2002EP1252158A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
10/30/2002EP1252157A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
10/30/2002EP1252155A1 Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
10/30/2002EP1252154A1 Heterocyclic amide derivatives
10/30/2002EP1252152A1 Urea compounds as inhibitors for vla-4
10/30/2002EP1252150A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
10/30/2002EP1252146A1 Amide compounds for inhibiting protein kinases
10/30/2002EP1252144A1 Substituted glutarimides and use thereof il-12 production inhibitors
10/30/2002EP1252143A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives
10/30/2002EP1252141A1 Tosylproline analogs as thymidylate synthase inhibitors
10/30/2002EP1252133A2 Pharmaceutical compounds
10/30/2002EP1251872A1 Compositions and methods for treating cell proliferation disorders
10/30/2002EP1251871A1 Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants
10/30/2002EP1251866A1 Combination of temozolomide and pegylated interferon-alpha for treating cancer
10/30/2002EP1251861A2 Physiologically active compositions of basidiomycotina and araliaceae extracts
10/30/2002EP1251859A1 Novel compounds
10/30/2002EP1251858A2 Podophyllotoxin compositions
10/30/2002EP1251850A2 Combination therapy for cancer
10/30/2002EP1251846A1 C-4 carbonate taxanes
10/30/2002EP1251845A1 Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof
10/30/2002EP1251840A2 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
10/30/2002EP1251836A2 Use of bvdu for inhibiting the growth of hyperproliferative cells
10/30/2002EP1251835A2 Closure of bacterial ghosts
10/30/2002EP1251829A1 Electrospun pharmaceutical compositions
10/30/2002EP1251828A1 Local drug delivery using photosensitizer-mediated and electromagnetic radiation-enhanced vascular permeability
10/30/2002EP1251739A2 Poly(dipeptide) as a drug carrier
10/30/2002EP1135193B1 Agents provided for treating tumors, based on liposomes, and containing tamoxifen
10/30/2002EP1017412A4 Genes coding proteins for early liver development and their use in diagnosing and treating liver disease
10/30/2002EP0862740B1 Oncogene fusion protein peptide vaccines
10/30/2002EP0835260B1 Antiproliferative protein from bacillus thuringiensis var. thuringiensis
10/30/2002EP0726911B1 Treatment of hematologic disorders with a igf-1/igfbp-3 complex
10/30/2002EP0695187B1 Inhibition, control and regression of angiogenesis with hyaluronic acid or hyaluronic acid and nsaid
10/30/2002EP0689449B1 Therapeutical compositions for use in humans, characterised by a combination of a muramyl peptide and a cytokine
10/30/2002CN1377424A Methods of reparing tandemly repeated DNA sequences and extending cell life-span using nuclear transfer
10/30/2002CN1377408A The PRV-1 gene and use thereof
10/30/2002CN1377347A 药学活性磺酰胺衍生物 Pharmaceutically active sulfonamide derivatives
10/30/2002CN1377346A Z-pyrazoline-5-ones
10/30/2002CN1377282A Fatty acid-anticancer conjugates and uses thereof
10/30/2002CN1377280A Diagnosis and treatment of neuroectodermal tumors
10/30/2002CN1377279A Use of soluble cosmetimulatory molecules to enhance immune responses
10/30/2002CN1377278A Prevention and treatment of amyloidogenic disease
10/30/2002CN1377277A Use of leptin in inhibition of endothelial cell proliferation
10/30/2002CN1377276A Protein polymerization inhibitors and methods of use
10/30/2002CN1377271A Use of thienopyrimidines
10/30/2002CN1377269A Vitronectin receptor antagonists
10/30/2002CN1377261A Treatment of immune diseases
10/30/2002CN1376664A Propynyl or diene diaryl compounds
10/30/2002CN1376503A Chinese medicine for treating cancers in digestive system and its preparing process
10/30/2002CN1376497A Qizhen capsule and its preparing process
10/30/2002CN1376468A Freeze dried hydroxy camptothecin powder for injection and its preparing process
10/30/2002CN1376464A Method for treating cancer with curcumin plus catechin
10/30/2002CN1093411C Anti-cancer medicinal composition and its preparing method
10/30/2002CN1093399C Small particle liposome aerosols for delivery of anti-cancer drugs
10/30/2002CA2383469A1 Treatment of t-cell mediated diseases
10/29/2002US6472526 Shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts or isomers thereof, in pharmaceutical composition and intermediates
10/29/2002US6472521 Oligonucleotides for the inhibition of human eg5 expression
10/29/2002US6472507 Carrier based drug delivery system
10/29/2002US6472435 Antitumor antiproliferation agent formed by amidation of carboxy acid with aromatic amine compound
10/29/2002US6472415 Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
10/29/2002US6472412 Compounds as PDE IV and TNF inhibitors
10/29/2002US6472403 αV integrin receptor antagonists
10/29/2002US6472396 Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
10/29/2002US6472385 Compositions and methods to enhance cancer chemotherapy in p53 defective tumors
10/29/2002US6472379 Angiogenesis inhibition
10/29/2002US6472376 Gene therapy
10/29/2002US6472375 DNA vaccine and methods for its use
10/29/2002US6472369 Anticancer compounds and methods
10/29/2002US6472368 Compounds and methods for modulating adhesion molecule function
10/29/2002US6472367 Compounds and methods for modulating OB-cadherin mediated cell adhesion
10/29/2002US6472195 Human kallikrein
10/29/2002US6472179 Nucleotide sequences coding fusion protein for use in the treatment of osteoporosis, cancers, and cachexia
10/29/2002US6472172 DNA encoding a novel human inhibitor-of-apoptosis protein
10/29/2002US6472165 Modulatory binding site in potassium channels for screening and finding new active ingredients
10/29/2002US6471987 Ligating band comprises an elastomeric layer and an inner drug releasing layer; chemotherapeutic agent for treating a mucosa, polyp or other growth
10/29/2002US6471968 Multifunctional nanodevice platform
1 ... 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 ... 2211